Research / CRVL / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-25-269721 Insurance
Cash 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$207.5M · CORE · VALID
Net-income growth 50th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.net_income
19.27% · CORE · VALID
Revenue growth 15th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
6.80% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 28 states Self-history eligible
Sep 30, 2021 3/3 normalized Level 3 Dec 31, 2021 3/3 normalized Level 3 Mar 31, 2022 3/3 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 3/3 normalized Level 3 Dec 31, 2022 3/3 normalized Level 3 Mar 31, 2023 3/3 normalized Level 3 Jun 30, 2023 3/3 normalized Level 3 Sep 30, 2023 3/3 normalized Level 3 Dec 31, 2023 3/3 normalized Level 3 Mar 31, 2024 3/3 normalized Level 3 Jun 30, 2024 3/3 normalized Level 3 Sep 30, 2024 3/3 normalized Level 3 Dec 31, 2024 3/3 normalized Level 3 Mar 31, 2025 3/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 4 Period transition
What moved in the state? Cash Increased
Previous $202.0M
Current $207.5M
Delta $5.4M Earnings Growth Decreased
Previous 26.22%
Current 19.27%
Delta -6.96% Revenue Growth Decreased
Previous 10.86%
Current 6.80%
Delta -4.06% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.